Previous Page  12 / 33 Next Page
Show Menu
Previous Page 12 / 33 Next Page
Page Background

Volume 4

Nano Research & Applications

ISSN: 2471-9838

Page 28


August 16-18, 2018 | Dublin, Ireland




Edition of International Conference on

Nanopharmaceutics and Advanced Drug Delivery



Nano Congress for

Future Advancements

Nano Congress 2018


Nano Drug Delivery 2018

August 16-18, 2018

Patrick J Sinko et al., Nano Res Appl 2018, Volume 4

DOI: 10.21767/2471-9838-C3-014

Nanotechnology approaches for intensifying localized combination therapy for precision treatment

of early stage breast cancer

Patrick J Sinko, Firas Al Zubaydi, In Heon Lee, Zoltan Szekely, Jennifer Holloway, Dayuan Gao


Hatem Sabaawy


Rutgers The State University of New Jersey, USA


Rutgers Cancer Institute of New Jersey, USA


uctal carcinoma

in situ

(DCIS) is a noninvasive breast cancer (BC) with possible microinvasions into the breast stroma.

DCIS accounts for more than 16% of new BC diagnoses in women. DCIS progresses to Invasive Ductal Carcinoma

(IDC) over time in 39-53% of patients, if left untreated. The vast majority of BC cases originate in the mammary duct. In

this presentation, a nanoscale delivery system will be described that utilizes transpapillary delivery to achieve molecularly

targeted, pathway-specific therapy in cancerous areas of the mammary duct. Our preliminary results with a nanosuspension

of ciclopirox (CPX) in an orthotopic model of BC established the concept that sustained ductal exposure could completely

suppress BC occurrence

in vivo

. For these studies polymeric NPs (nanoparticles) as well as lipid-polymer hybrid (LPH) NPs

were the primary delivery vehicles. In order to achieve sustained precision treatment, HER2, transferrin receptor and/or EGFR

were targeted using peptide ligands covalently bound to the surface of NPs. Ligand surface densities of 5% and 10% were

evaluated and it was found that surface functionalized NPs enhanced binding and uptake into target cells. Cytoxicity was

significantly increased with EGFR or TfR targeted NPs as compared to CPX alone or non functionalized CPX-loaded NPs. A

synergistic effect was observed when CPX was administered with gedatolisib, a PI3K/Akt/mTOR inhibitor resulting in a dose

reduction index of ~6. In addition, the treatments were effective not only in BC cells but also cancer stem-like cells. Our efforts

in addition to describing these studies and results, the engineering of the NPs to enhance ductal retention and specificity will

also be described.

Recent Publications

1. Gu Z et al. (2018) The effect of size and polymer architecture of doxroubicin-poly(ethylene) glycol conjugate

nanocarries on breast duct retention, potency and toxicity. European Journal of Pharmaceutical Sciences. 121:118-

125. Doi 10.1016/j.ejps.2018.04.033.

2. Lee I H et al. (2018) Design and evaluation of a CXCR4 targeting peptide 4DV3 as an HIV entry inhibitor and a ligand

for targeted drug delivery. European Journal of Pharmaceutics and Biopharmaceutics. pii: S0939-6411(18)30013-

30014. Doi: 10.1016/j.ejpb.2018.06.004.

3. Singh Y D et al. (2012) Influence of molecular size on the retention of polymeric nanocarrier diagnostic agents in

breast ducts. Pharmaceutical Research. 29(9):2377-2388. Doi:10.1007/s11095-012-0763-z.

4. Singh Y D et al. (2011) Noninvasive detection of passively targeted poly(ethylene glycol) nanocarriers in tumors.

Molecular Pharmaceutics. 9(1):144-155. Doi:10.1021/mp2003913.


Patrick J Sinko is a Pharmacist (BS, Rutgers 1982) and a Pharmaceutical Scientist (PhD, University of Michigan 1988). He joined Rutgers, The State University of

New Jersey in 1991 and rose through the academic ranks where he is currently a Distinguished Professor (II) and the Parke-Davis Endowed Chair in Pharmaceutics

and Drug Delivery in the Ernest Mario School of Pharmacy. He is the Principal Investigator of an active research laboratory that focuses on biopharmaceutics,

pharmaceutical formulations and molecular-, nano- and micro-scale drug delivery with specific applications to the treatment or prevention of HIV/AIDS, breast, brain

and lung cancer, chemical terrorism countermeasures. He has received prestigious National Institutes of Health FIRST and MERIT awards and his lab has been

continuously funded by the NIH for over 25 years.

[email protected]